Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Celldex Therapeutics, Inc. (NASDAQ: CLDX).

Full DD Report for CLDX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CLDX)

Celldex beats by $0.11, misses on revenue
Celldex (NASDAQ: CLDX ): Q3 GAAP EPS of -$0.04 beats by $0.11 . More news on: Celldex Therapeutics, Inc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 07 2018 17:15
Celldex Provides Corporate Update and Reports Third Quarter 2018 Results
HAMPTON, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018. “We made considerable progress in the third quarter, particularly in the development program fo...
Source: GlobeNewswire
Date: November, 07 2018 16:01
Today's Research Reports on Trending Tickers: Celldex Therapeutics and Inovio Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike in September. The Dow Jones Industrial Average dropped 0.34 percent to close at 25...
Source: ACCESSWIRE IA
Date: August, 23 2018 08:00
Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q2 2018 Results - Earnings Call Transcript
Celldex Therapeutics, Inc. (CLDX) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET Executives Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Founder, President, Chief Executive Officer and Director Tibor Keler - Founder, ...
Source: SeekingAlpha
Date: August, 08 2018 22:17
Celldex beats by $0.03, beats on revenue
Celldex (NASDAQ: CLDX ): Q2 EPS of -$0.11 beats by $0.03 . Revenue of $2.8M (-26.9% Y/Y) beats by $0.5M . Press Release More news on: Celldex Therapeutics, Inc, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: August, 08 2018 16:04
Celldex Provides Corporate Update and Reports Second Quarter 2018 Results
HAMPTON, N.J., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2018. The Company will host a conference call at 4:30 p.m. ET today to provide an in-depth update on its pipeline ...
Source: GlobeNewswire
Date: August, 08 2018 16:01
Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call
HAMPTON, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2018 financial results on Wednesday, August 8, 2018 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day t...
Source: GlobeNewswire
Date: August, 02 2018 08:01
Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Myriad Genetics, Inc. (NASDAQ:MYGN), Celldex Therapeutics, Inc. (NASDAQ:C...
Source: GlobeNewswire
Date: August, 01 2018 07:45
Initiating Free Research Reports on Celgene and Three Other Biotech Equities
Stock Research Monitor: CARA, CLDX, and CORT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on CELG sign up now at www.wallstequities.com/registration . On Thursday, benchmark US indices were mixed as the NASDAQ Composite closed the trading session down 1.01%...
Source: ACCESSWIRE IA
Date: July, 27 2018 07:35
What Does Breakthrough Therapy Designation Really Mean For My Company?
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th...
Source: SeekingAlpha
Date: June, 23 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.25880.2750.300.2551,847,382
2018-12-070.27850.25530.27850.25511,123,507
2018-12-060.28050.27070.2870.26791,238,059
2018-12-050.290.28070.2950.281,349,124
2018-12-040.290.2820.2950.281,210,676

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10346,807623,20955.6486Short
2018-12-07208,202361,20157.6416Short
2018-12-06300,066383,87378.1680Short
2018-12-04187,684550,23934.1095Cover
2018-12-03460,827992,95046.4099Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CLDX.


About Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Logo for Celldex Therapeutics, Inc. (NASDAQ: CLDX)

Not available

 

Contact Information

 

 

Current Management

  • Una S. Ryan / President, CEO, COO
  • Avery W. Catlin / CFO, Secretary

Current Share Structure

  • Market Cap: $99,541,580 - 05/15/2018
  • Issue and Outstanding: 141,073,668 - 02/28/2018

 


Recent Filings from (NASDAQ: CLDX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 20 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (NASDAQ: CLDX)

Daily Technical Chart for (NASDAQ: CLDX)


Stay tuned for daily updates and more on (NASDAQ: CLDX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CLDX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CLDX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CLDX and does not buy, sell, or trade any shares of CLDX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/